News

Morning briefing: “Strap in” for Grainger battle as Saba follows Mike Ashley with 5% stake; Saba target Workspace cuts dividend; Molten backs Isar Aerospace; IBT and BIOG chalk up sixth bid as GSK buys Nuvalent; plus Helical, Tritax Big Box

person reading a mobile

Saba Capital has bought a 5% position in Grainger (GRI), the £1.1bn residential landlord that has been trading at around a 50% discount to net asset value. Shares in the company rose 4.2% to 159.7p after the activist hedge fund’s stake, mostly held in swap derivatives, was disclosed yesterday afternoon. Saba completed buying the position on 4 June and notified Grainger on Monday. Last month, Mike Ashley, founder of Frasers (FRAS), the Sports Direct owner, bought a 4.2% stake in the company.

Workspace (WKP), the flexible office space provider fighting efforts by activist Saba to wind it down, has cut its final dividend by 12.1% to 16.7p per share, down from 19p, reducing the total pay-out for the year to 31 March by 8.1% to 26.1p from 28.4p. The declaration came in annual results showing a 7.1% fall in net rental income to £113.4m as the company sold non-core properties and recycled its capital into better opportunities. “We have an exciting opportunity ahead to reposition our business and elevate our offer, work that has already started, so that we fully address the changing needs of occupiers today,” said chief executive Charlie Green. There was no mention of the general meeting requisitioned by 21% shareholder Saba to replace Workspace’s board.

Molten Ventures (GROW) has invested €30m into the €270m series-D funding round announced by Isar Aerospace, a German satellite launch company that it described as “one of the most significant opportunities” in the European space technology sector. Molten shares yesterday jumped over 17% to 630.5p, lifting its value to £1.1bn, after ICEYE, a holding, announced a quadrupling in its valuation to over €10bn following the Finnish satellite operator’s latest funding round.

International Biotechnology Trust (IBT) and Biotech Growth (BIOG) were small beneficiaries of GSK’s $10.6bn acquisition of US cancer drug developer Nuvalent yesterday. Announcing its biggest ever purchase, the UK drugs company said it would pay $124 per share in cash to shareholders in the Boston-based company, a premium of 40% to the last closing price. Nuvalent was 0.4% of IBT’s net asset value and 1.5% of BIOG. This is the sixth bid both trusts have seen for portfolio companies this year. “With the drivers of robust M&A activity firmly in place, we expect deal flow to remain strong and will continue to position our portfolio to benefit from ongoing activity and deliver returns to shareholders,” said Schroders fund managers Ailsa Craig and Marek Poszepczynski.

Office developer Helical (HLCL) has completed regears and a new letting across six floors at The Bower near Old Street, London, with two of its biggest occupiers Fin (formerly Intercom) and Fresha. The deals involving 60,000 square feet of space will generate £4.5m of annual rent.

Tritax Big Box REIT (BBOX) now expects the Ministry of Housing, Communities and Local Government to announce the planning decision on its data centre at Manor Farm, Heathrow on or before 7 July. 

Stay a step ahead. Our daily newsletter brings you the latest on investment trusts and active ETFs. Subscribe here.

Gavin Lumsden
Written By Gavin Lumsden

Head of News

Leave a Reply

Your email address will not be published. Required fields are marked *